Liquid Biopsy Market Size  (2026 – 2030)

The Liquid Biopsy Market was valued at approximately USD 13.60 Billion in 2025 and is projected to reach a market size of around USD 25.05 Billion by the end of 2030. Over the forecast period of 2026-2030, the market is expected to grow at a CAGR of about 13%.

The Liquid Biopsy Market covers non-invasive diagnostic testing that analyses circulating biomarkers in body fluids to detect and monitor diseases. It focuses mainly on cancer applications using blood, urine, or saliva samples. Technologies such as sequencing and PCR identify genetic and molecular changes in real time. The market enables early detection, treatment selection, and disease monitoring without invasive tissue procedures, supporting precision medicine adoption across global healthcare systems and clinical decision workflows effectively.

This market includes clinical liquid biopsy tests using blood, urine, and saliva samples for oncology, prenatal, and transplant monitoring applications. It covers biomarker analysis such as ctDNA, CTCs, and exosomes using sequencing and PCR technologies. It excludes research-only use, tissue biopsy procedures, and general lab diagnostics not tied to clinical decision-making. Revenue is counted at the clinical testing level to avoid duplication across technologies and service layers globally.

Liquid biopsy has shifted from experimental use to routine clinical consideration in oncology care. Blood-based testing is now preferred for monitoring disease progression. Technology improvements have increased sensitivity and reduced turnaround time. Clinical focus is moving toward early detection and real-time monitoring. Adoption is expanding beyond cancer into prenatal and transplant applications across global healthcare systems steadily.

Buyers must focus on clinical utility over technical capability. The decision now depends on accuracy, turnaround time, and integration into care workflows. Non-invasive testing value must be measured against real outcomes, not just innovation claims or laboratory performance metrics alone.

Key Market Insights

• Liquid biopsy identified actionable mutations in cases where tissue biopsy was unavailable in over 14% of evaluated cancer patients.
• Lung cancer accounts for approximately 61% of liquid biopsy testing cases in clinical oncology practice settings.
• Colorectal cancer contributes nearly 27% of liquid biopsy applications, reflecting strong use in gastrointestinal oncology diagnostics.
• Liquid biopsy detects clinically relevant genomic alterations in up to 90% of tested samples, supporting its role in precision oncology workflows.
• Around 47% of analysed ctDNA samples in clinical settings are linked to lung malignancies, indicating concentration of usage in specific cancer types.
• ctDNA mutation detection identified new resistance mutations in about 45% of monitored cancer cases during treatment follow-up.
• Clinical studies show liquid biopsy positivity rates of approximately 18% in patients undergoing mutation profiling for targeted therapy decisions.
• Stage IV cancer patients represent nearly 83% of liquid biopsy testing populations, highlighting its strong application in advanced disease monitoring.
• ctDNA analysis enables detection of multiple mutation types, with nonsynonymous variants observed in over 90% of tested patient samples.

Research Methodology

Scope & definitions

• Defines liquid biopsy as analysis of circulating biomarkers for clinical diagnostic and monitoring applications.
• Includes ctDNA, CTCs, and exosomes across oncology and selected non-oncology clinical use cases.
• Excludes research-only applications, non-clinical genomics, and unrelated laboratory tools.
• Covers global geography with defined historical and forecast timeframe.
• Applies MECE segmentation across biomarker type, technology, sample type, and application.
• Establishes a standardized data dictionary for consistent metrics and terminology.
• Prevents double counting by capturing value at a single clinical testing transaction layer.

Evidence collection (primary + secondary)

• Primary interviews conducted across diagnostic labs, hospitals, technology providers, and clinical experts.
• Secondary sources include company filings, peer-reviewed journals, and regulatory publications.
• Uses data from organizations such as U.S. Food and Drug Administration and World Health Organization.
• Incorporates inputs from relevant regulators/standards bodies/industry associations specific to Liquid Biopsy Market (named in-report).
• Ensures all insights are backed by verifiable sources with source-linked evidence within the report.

Triangulation & validation

• Combines bottom-up revenue aggregation with top-down market estimation approaches.
• Reconciles findings with company financial disclosures and segment-level reporting.
• Validates assumptions through expert interviews across the value chain.
• Resolves conflicting inputs using credibility weighting and consistency checks.

Presentation & auditability

• Presents outputs in structured tables with clear segmentation and definitions.
• Documents assumptions and methodologies for full transparency and traceability.
• Provides source-linked references enabling auditability and LLM-citation readiness.

Market Drivers

The increasing preference for non-invasive diagnostic techniques is a major driver of the Global Liquid Biopsy Market.

Traditional tissue biopsies are invasive, time-consuming, and sometimes not feasible due to tumour location or patient condition. Liquid biopsy offers a safer and more convenient alternative by enabling disease detection through simple blood samples. This improves patient compliance and allows frequent monitoring of disease progression and treatment response. The growing burden of cancer worldwide is further driving demand for efficient diagnostic solutions. Healthcare providers are increasingly adopting liquid biopsy to support early detection and personalized treatment planning. Advancements in detection technologies are also improving accuracy, supporting wider clinical adoption across healthcare systems globally.

Continuous advancements in genomic technologies are further driving the growth of the Global Liquid Biopsy Market.

Improved sequencing techniques and PCR-based methods are enhancing the sensitivity and specificity of biomarker detection. These advancements allow clinicians to identify genetic mutations and tailor treatments based on individual patient profiles. The growing emphasis on precision medicine is encouraging healthcare providers to adopt liquid biopsy as a routine diagnostic tool. In addition, integration of bioinformatics and data analytics is improving interpretation of complex genomic data. Increasing investments in research and development are further supporting innovation, enabling the expansion of liquid biopsy applications beyond oncology into broader disease areas globally.

Market Restraints

High cost and technical complexity remain key challenges in the Global Liquid Biopsy Market. Advanced technologies such as next-generation sequencing and digital PCR require significant investment in equipment, skilled personnel, and infrastructure. Many healthcare facilities, particularly in developing regions, face limitations in adopting these solutions due to budget constraints. In addition, variability in biomarker detection and lack of standardized protocols can impact test accuracy and reliability. Regulatory approval processes are also complex and time-consuming, delaying market entry for new solutions. Limited reimbursement policies in several regions further restricts adoption. These challenges collectively slow down widespread clinical implementation and create barriers for smaller laboratories and healthcare providers.

Market Opportunities

expanding applications in early disease detection and monitoring present strong opportunities for the Global Liquid Biopsy Market. Increasing research in minimal residual disease detection and recurrence monitoring is driving demand for highly sensitive diagnostic tools. Liquid biopsy enables continuous, real-time tracking of disease progression, which is critical for improving patient outcomes. Emerging markets offer significant growth potential due to improving healthcare infrastructure and rising awareness of advanced diagnostics. Collaborations between biotechnology companies, healthcare providers, and research institutions are accelerating innovation.

How this market works end-to-end

• A clinical need is identified, typically in oncology, prenatal screening, or transplant monitoring.
• A patient sample is collected, most commonly blood, followed by urine or saliva where required.
• Biomarkers such as ctDNA, CTCs, or exosomes are isolated from the sample.
• The extracted material is processed using sequencing, PCR, or microarray technologies.
• Raw molecular data is generated and passed into analysis pipelines.
• Data analysis identifies genetic alterations or disease-specific signals.
• Results are interpreted into clinically actionable insights for physicians.
• Reports are delivered to hospitals, diagnostic labs, or research institutes.
• Clinical decisions are made based on disease detection, progression, or treatment response.

What matters most when evaluating claims in this market

The decision lens

• Define the clinical use case before selecting biomarker or technology.
• Evaluate sample type suitability based on patient condition and workflow needs.
• Compare ctDNA, CTC, and exosome capabilities based on diagnostic goals.
• Assess technology performance across sequencing and PCR methods in real settings.
• Check integration with clinical reporting systems and decision workflows.
• Validate vendor claims through real-world clinical adoption and outcomes.

The contrarian views

• Non-invasive does not always mean clinically superior across all use cases.
• Many growth claims ignore differences between oncology and non-oncology adoption.
• Technology comparisons often overlook bottlenecks in sample preparation and analysis.
• Cost advantages are frequently overstated without including data interpretation expenses.
• Early detection claims are often based on limited validation studies.
• Market estimates sometimes mix research and clinical usage, inflating demand signals.

Practical implications by stakeholder

Hospitals and Clinics

• Focus on clinical outcomes and ease of integration into treatment workflows.
• Require reliable reporting rather than experimental or exploratory testing.

Diagnostic Laboratories

• Prioritize throughput, cost control, and consistent test accuracy.
• Invest in advanced data analysis capabilities to maintain competitiveness.

Academic and Research Institutes

• Use liquid biopsy to validate new biomarkers and expand clinical applications.
• Act as early adopters for emerging technologies and testing approaches.

Technology Providers

• Must offer complete solutions, including analysis and reporting tools.
• Need to prove clinical utility beyond technical innovation.

LIQUID BIOPSY MARKET REPORT COVERAGE:

Market Segmentation

Liquid Biopsy Market – By Biomarker Type

• Introduction/Key Findings
• Circulating Tumor DNA (ctDNA)
• Extracellular Vesicles (Exosomes)
• Circulating Tumor Cells (CTCs)
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Circulating Tumor DNA (ctDNA) is the largest segment due to its strong clinical utility and extensive validation in cancer diagnostics and monitoring. ctDNA enables detection of tumor-specific genetic mutations from blood samples with high sensitivity and specificity, making it highly suitable for non-invasive testing. It is widely used for treatment selection, detection of minimal residual disease, and monitoring of therapy response in real time. Its compatibility with advanced sequencing technologies further enhances its reliability and scalability. Increasing adoption in oncology, along with growing regulatory approvals and clinical guidelines, continues to support its dominant position. As healthcare systems shift toward precision medicine, ctDNA remains the most established and widely adopted biomarker type globally.

Extracellular Vesicles (Exosomes) represent the fastest growing segment due to their ability to provide a more comprehensive biological snapshot of disease conditions. Exosomes carry a wide range of molecular contents, including DNA fragments, RNA, and proteins, enabling multi-dimensional analysis through a single sample. This makes them highly valuable for early disease detection and complex disease profiling. Rapid advancements in isolation technologies and analytical methods are improving their clinical applicability. Increasing research investments and growing interest in non-invasive diagnostics are accelerating adoption. Their potential beyond oncology, including neurological and metabolic disorders, is further expanding their relevance, driving strong growth across both clinical and research applications worldwide.

Liquid Biopsy Market – By Technology

• Introduction/Key Findings
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Microarray Technology
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Next-Generation Sequencing (NGS) is the largest segment due to its ability to deliver comprehensive genomic insights with high accuracy and throughput. It enables simultaneous analysis of multiple genes and mutations, which is critical for complex disease diagnostics, particularly in oncology. NGS supports detailed tumor profiling, identification of actionable mutations, and personalized treatment planning. Continuous advancements in sequencing chemistry, automation, and bioinformatics have improved efficiency and reduced turnaround time. Its widespread adoption in clinical laboratories and strong integration with precision medicine initiatives further reinforce its leadership position. As demand for multi-gene testing increases, NGS remains the backbone technology in liquid biopsy diagnostics globally.

Next-Generation Sequencing (NGS) is also the fastest growing segment due to its expanding role in advanced clinical applications and ongoing technological innovation. The ability to detect low-frequency mutations with high sensitivity makes it highly effective for early cancer detection and monitoring disease progression. Increasing affordability and improvements in data analysis tools are making NGS more accessible to a wider range of healthcare providers. Growing investments in genomic infrastructure and increasing adoption in emerging markets are further accelerating growth. Additionally, integration with artificial intelligence for data interpretation is enhancing diagnostic accuracy, positioning NGS as a key driver of future advancements in liquid biopsy technology worldwide.

Liquid Biopsy Market – By Sample Type

• Introduction/Key Findings
• Blood
• Urine
• Saliva
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Liquid Biopsy Market – By Clinical Application

• Introduction/Key Findings
• Oncology Testing
• Prenatal Testing
• Organ Transplant Monitoring
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Liquid Biopsy Market – By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America is the largest region in the Liquid Biopsy Market due to its advanced healthcare infrastructure and strong adoption of precision medicine approaches. The region benefits from high awareness of non-invasive diagnostic technologies and early integration of liquid biopsy into clinical practice, particularly in oncology. Strong presence of specialized diagnostic laboratories and continuous investments in genomic research further support market growth. Favourable regulatory frameworks and increasing availability of reimbursement for certain tests are also encouraging adoption. In addition, collaborations between research institutions and healthcare providers are accelerating innovation, making North America the most established and dominant regional market globally.

Asia Pacific is the fastest growing region in the Liquid Biopsy Market driven by rapidly improving healthcare infrastructure and rising demand for advanced diagnostic solutions. Increasing prevalence of cancer and growing awareness of early detection are major factors supporting adoption. Governments in countries such as China, India, and Japan are investing in precision medicine and expanding access to genomic testing. Cost advantages and a large patient population further contribute to strong growth potential. In addition, increasing participation of local players and expanding diagnostic capabilities are accelerating market expansion, making Asia Pacific a key high-growth region in the global liquid biopsy landscape.

Key Players

1. Guardant Health, Inc.
2. Foundation Medicine, Inc.
3. Bio-Rad Laboratories, Inc.
4. QIAGEN N.V.
5. F. Hoffmann-La Roche Ltd
6. Thermo Fisher Scientific Inc.
7. Illumina, Inc.
8. Exact Sciences Corporation
9. Myriad Genetics, Inc.
10. Natera, Inc.

Latest Market News

March 2026: BillionToOne launched advanced liquid biopsy applications platform.

BillionToOne expanded its Northstar platform by launching two new liquid biopsy applications focused on therapy selection and treatment safety. The new additions enhance detection of clinically actionable alterations and support chemotherapy decision-making. This development strengthens the platform’s clinical utility by improving diagnostic depth and enabling more comprehensive cancer profiling within a single integrated testing workflow.

April 2025: Guardant Health collaborated for oncology drug development using liquid biopsy.

Guardant Health entered a multi-year collaboration with Pfizer to support development and commercialization of cancer therapies using liquid biopsy platforms. The partnership focuses on leveraging circulating tumour DNA for treatment monitoring and clinical research. This initiative strengthens integration of liquid biopsy in drug development and expands its role in precision oncology across global clinical and pharmaceutical ecosystems.

Questions buyers ask before purchasing this report

What decisions can this report actually support?

This report supports decisions related to investment, product positioning, and market entry. It helps buyers understand where clinical demand exists and where it is still developing. Instead of focusing only on growth expectations, it highlights real adoption patterns and workflow challenges. This allows decision-makers to prioritize segments with proven clinical use and avoid overestimating opportunities in early-stage applications.

How is this different from general diagnostics market reports?

General diagnostics reports often combine multiple testing methods and applications, making it hard to isolate liquid biopsy trends. This report focuses only on non-invasive biomarker-based testing. It separates biomarker types, technologies, and clinical uses clearly. This structure reflects how decisions are made in real clinical settings, improving clarity and reducing confusion for buyers evaluating specific opportunities.

Does the report reflect real clinical adoption?

Yes, the report emphasizes real-world usage across hospitals, diagnostic laboratories, and research institutes. It distinguishes between widely adopted tests and those still in early validation stages. This helps buyers avoid relying on theoretical potential and instead focus on segments with actual clinical traction. It provides a more practical view of the market landscape and its current maturity level.

How are different technologies compared in the report?

Technologies such as sequencing, PCR, and microarrays are compared based on their role in clinical workflows. The report does not rank them purely on technical performance. Instead, it evaluates how each technology performs in real diagnostic scenarios. This includes accuracy, speed, cost, and integration. This approach helps buyers select technologies that fit their operational and clinical requirements.

Can this report guide expansion into new regions?

Yes, the report provides a structured view of regional differences in adoption and infrastructure. It highlights how healthcare systems, awareness, and investment levels vary across regions. This helps buyers identify markets where liquid biopsy adoption is growing and where barriers still exist. It supports informed expansion strategies by aligning opportunities with real market readiness.

How does the report handle overlapping segments?

The report uses a strict structure to avoid overlap between biomarker types, technologies, and applications. Each segment is defined clearly, ensuring no double counting of revenue or demand. This improves accuracy and transparency. Buyers can rely on consistent data that reflects actual market distribution rather than inflated or duplicated estimates.